ResearcherInstitut Gustave RoussyNo recent work listed

Rita Khoury

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0009-0001-2696-3580; OpenAlex author ID A5048027221. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2023: 2 papers

Papers 2

KRAS G12C mutation: from black sheep to key player in pancreatic cancer treatment First author DOI 10.2217/fon-2023-0067 ↗
NALIRIFOX in the upfront setting of metastatic pancreatic cancer: can FOLFIRINOX finally be dethroned? Co-author DOI 10.2217/fon-2023-0088 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Rebecca Ibrahim · 2 shared papers, 2023 · strength 0.48
- Paper KRAS G12C mutation: from black sheep to key player in pancreatic cancer treatment DOI 10.2217/fon-2023-0067 ↗
- Paper NALIRIFOX in the upfront setting of metastatic pancreatic cancer: can FOLFIRINOX finally be dethroned? DOI 10.2217/fon-2023-0088 ↗
Tarek Assi · 2 shared papers, 2023 · strength 0.48
- Paper KRAS G12C mutation: from black sheep to key player in pancreatic cancer treatment DOI 10.2217/fon-2023-0067 ↗
- Paper NALIRIFOX in the upfront setting of metastatic pancreatic cancer: can FOLFIRINOX finally be dethroned? DOI 10.2217/fon-2023-0088 ↗
Axel Le Cesne · 2 shared papers, 2023 · strength 0.48
- Paper KRAS G12C mutation: from black sheep to key player in pancreatic cancer treatment DOI 10.2217/fon-2023-0067 ↗
- Paper NALIRIFOX in the upfront setting of metastatic pancreatic cancer: can FOLFIRINOX finally be dethroned? DOI 10.2217/fon-2023-0088 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.